AXA, IBM, Fondation Suez: three major boosts for the Institut Pasteur's COVID-19 research

Visit to the Institut Pasteur by the CEO of the AXA Group, committed to supporting the Institut Pasteur since the start of the COVID-19 epidemic

 

More than 15 years ago, the AXA Group set up the AXA Research Fund with the aim of supporting outstanding scientists and research institutions worldwide. The Group is particularly interested in risks, whether environmental, socio-economic or impacting human life and health. So it was a logical step for them to support the Institut Pasteur's research on COVID-19 from the outset of the pandemic.

On June 15, Thomas Buberl, CEO of AXA, George Stansfield, Deputy CEO, and some AXA staff members visited the Institut Pasteur. After highly constructive discussions with Institut Pasteur President Stewart Cole and Simon Cauchemez, Head of the Mathematical Modeling of Infectious Diseases Unit, they visited the National Reference Center (CNR) for Respiratory Viruses.

Find out more about AXA

 

The Institut Pasteur and IBM use artificial intelligence to speed up COVID-19 drug discovery

The Institut Pasteur, which specializes in the prevention and treatment of infectious diseases, and IBM have established a skills sponsorship scheme to speed up the search for therapeutic treatments for the COVID-19 pandemic using artificial intelligence. The aim is to find an antiviral drug that will prevent the virus from entering human cells. This will require the identification of drug candidate structures.
 

Read the press release

 

The Fondation Suez supports an analytical program investigating the spread of SARS-CoV-2 in Senegal, led by the Institut Pasteur de Dakar in conjunction with the Institut Pasteur

Thanks to the support of the Fondation Suez, seroepidemiological studies were launched back in July 2020 by the Institut Pasteur de Dakar in Senegal as part of efforts to tackle the COVID-19 pandemic. The aim of these comparative studies on the prevalence of anti-SARS-CoV-2 antibodies was to help identify risk factors associated with the spread of the SARS-CoV-2 virus in populations living in areas of active transmission and in areas with no documented local transmission. The program is being conducted by the Institut Pasteur de Dakar in collaboration with the Senegalese Ministry of Health and Social Action, the National Blood Transfusion Center in Senegal and the Institut Pasteur in Paris.

Press release coming soon